Medicus Bets on Melanoma ADC After Pfizer Deal
Medicus has named its melanoma antibody-drug conjugate a 'strategic priority' after closing a deal with Pfizer, concentrating resources on the program.
Topic
Oncology
Topic
Oncology
Obsidian to Present Melanoma Therapy Data at November Conference
Obsidian will present data on its melanoma therapy at a November conference, marking the next disclosure point for its cutaneous…
Merck Reports First Positive Phase 3 for Personalized mRNA Melanoma Therapy
Merck posts the first positive Phase 3 result for a personalized mRNA melanoma therapy, advancing individualized neoantigen immun…
FDA Advisory Committee Backs Melanoma Therapy After Two Rejections
An advanced melanoma therapy that failed twice in prior reviews has won a favorable FDA advisory committee vote, reviving its pat…
Iovance Shares Jump on Rising Demand for Melanoma Cell Therapy
Iovance Biotherapeutics shares surged after Barron's reported strong demand for its melanoma drug is driving company growth, sign…
Moderna Shares Surge 29.1% on Melanoma Vaccine Data
Moderna stock jumped 29.1% after reported melanoma vaccine success and Middle East expansion talks, boosting market confidence in…
Regeneron Shares Fall as Skin Cancer Therapy Misses in Late-Stage Trial
Regeneron shares dropped after a skin cancer treatment failed a late-stage trial. Details on the drug, indication and endpoint pe…
VA Researchers Identify Potential New Melanoma Treatment Pathway
VA researchers report a possible new melanoma treatment, a cancer with service-connected status; details on trial design and mech…
Naturally Occurring Molecule May Help Outsmart Melanoma, UC Researchers Say
University of California researchers report a naturally occurring molecule may help outsmart melanoma, pointing to a possible new…